

Research Article

High prevalence of deep venous thrombosis in non-severe COVID-19 patients hospitalized for a neurovascular disease

Olivier Rouyer^{a,b,c}, Irène Nora Pierre-Paul^a, Amadou Talibe Balde^a, Damaris Jupiter^a, Daniela Bindila^a,
Bernard Geny^{b,c}, Valérie Wolff^{a,c}

^aStroke Unit, Strasbourg University Hospital; ^bDepartment of Physiology and Functional Explorations, Strasbourg University Hospital; ^cEA 3072, Federation of Translational Medicine of Strasbourg, University of Strasbourg; 67000 Strasbourg, France.

Short Title: Venous thrombosis in stroke unit with non-severe COVID-19

Corresponding Author: Olivier Rouyer, Stroke Unit, Strasbourg University Hospital, avenue Molière, 67000 Strasbourg, France.

Tel: (33) 03 88 11 67 68

E-mail: olivier.rouyer@chru-strasbourg.fr

Number of Tables: 1

Word count: 1149

Keywords: neurovascular disease - stroke unit - COVID-19 - Doppler ultrasound scanning - deep venous thrombosis

1 **Abstract**

2 **Introduction:** Severe SARS-CoV-2 infection, responsible for COVID-19, is accompanied by venous
3 thromboembolic events particularly in intensive care unit. In non-severe COVID-19 patients affected
4 by neurovascular diseases, the prevalence of deep venous thrombosis (DVT) is unknown. The aim of
5 or study was to report data obtained after systematic Doppler ultrasound scanning (DUS) of lower
6 limbs in such patients.

7 **Methods:** Between March 20 and May 2, 2020, consecutive patients with neurovascular diseases
8 with non-severe COVID-19 were investigated with a systematic bedside DUS.

9 **Results** Thirteen patients were enrolled including 10 acute ischemic strokes, one transient ischemic
10 attack, one cerebral venous thrombosis and one haemorrhagic stroke. At admission the median
11 National Institute of Health Stroke Scale (NIHSS) was of 6 (IQR, 0-20). We found a prevalence of
12 38.5% of asymptomatic calves' DVT (n=5) during the first week after admission despite
13 thromboprophylaxis. Among them, one patient had a symptomatic pulmonary embolism. Two
14 patients died during hospitalization but the outcome was favourable in the others with a discharge
15 median NIHSS of 1 (IQR, 0-11).

16 **Discussion/Conclusion:** Despite thromboprophylaxis, systematic bedside DUS showed a high
17 prevalence of 38.5% of DVT in non-severe COVID-19 patients with neurovascular diseases. Therefore,
18 we suggest that this non-invasive investigation should be performed in all patients of this category.

19 **Introduction**

20 The coronavirus disease 2019 (COVID-19) is characterized by a high prevalence of venous
21 thromboembolism, particularly in patients with severe illness admitted in intensive care unit [1,
22 2]. Systematic venous lower limbs Doppler ultrasound scanning (DUS) in COVID patients
23 showed a high prevalence of deep venous thrombosis (DVT) from 14.7% up to 85.4% [3, 4].
24 Furthermore, high pulmonary embolism rate in stroke patients with COVID-19 was recently
25 reported [5], thus questioning the increased risk of thromboembolism in such cases. We aimed
26 to determine the prevalence of DVT in non-severe COVID-19 patients hospitalized for a
27 neurovascular disease using systematic bedside DUS of lower limbs in a stroke unit.

28 **Materials and Methods**

29 Thirteen consecutive patients with neurovascular diseases and non-severe COVID-19, admitted in the
30 stroke unit of Strasbourg University Hospital between March 20 and May 2, 2020, were investigated.
31 COVID-19 was confirmed by RT-PCR and/or chest computed tomography (CT-scan) [6]. DUS of the
32 entire lower limbs venous system was performed at admission and subsequently on days 7 and 14 by
33 the same experimented practitioner (OR) using an IE33 Sonographer device (Philips, Bothell, WA,
34 USA). The approval for this study was obtained from the local ethics committee of the Strasbourg
35 University Hospital (reference CE-2020-111) and verbal informed consent was obtained from each
36 patient. This study is recorded in clinicaltrials.gov. (Unique identifier: NCT04452422).

37 **Results**

38 Patients' characteristics are reported in the Table. Brain magnetic resonance imaging showed 10
39 ischemic strokes (76%), one cerebral venous thrombosis (8%), and was normal in one patient leading
40 to the diagnosis of transient ischemic attack (8%). Brain CT-scan showed a cerebellar hematoma in
41 one patient (8%). A large vessel occlusion was found in 5 patients and in 7 the carotid territory was
42 affected. The remaining patient out of 13 had an occlusion of the ophthalmic artery. The patients
43 received the following treatments: alteplase alone (n=1), aspirin alone (n=3), endovascular procedure
44 alone (n=2) or combined endovascular procedure with intra-arterial alteplase (n=1) or intravenous
45 alteplase (n=3). Cerebral venous thrombosis was treated by effective anticoagulation, haemorrhagic
46 stroke by reversal anticoagulation.

47 Nine patients received thromboprophylaxis and 3 received effective anticoagulation. One was not
48 treated by anticoagulant because he could walk around.

49 The median National Institute of Health Stroke Scale (NIHSS) was of 6 (IQR, 0-20) at admission. The
50 neurological outcome was favourable in 11 cases and the median NIHSS for discharge was of 1 (IQR,

51 0-11). One patient stayed five days in intensive care unit for monitoring because of a worsening
52 dyspnoea. Two patients died because septicaemia complications for one and terminal phase of a
53 newly discovered cancer.

54 DUS showed an acute asymptomatic calf DVT in 2 patients at admission and in 3 others at day 7. At
55 day 14, no more thrombotic event was noticed. Among the 5 patients with DVT, one patient with a
56 complicated pulmonary embolism was treated by effective anticoagulation, one patient continued
57 the thromboprophylaxis treatment due to muscular calf vein location. On the remaining 3 patients,
58 the effective anticoagulation was contra-indicated because of a haemorrhagic cerebral
59 transformation (n=2) or by a digestive bleeding (n=1), leading to the use of a cava filter in one patient
60 and of thromboprophylaxis for all. Elastic stocks were used in all cases to prevent DVT.

61 **Discussion**

62 The main finding of our study is a high prevalence of 38.5% of asymptomatic DVT (n=5) in patients
63 with neurovascular diseases and non-severe COVID-19 in our stroke unit. To our knowledge this is
64 the first study exploring venous lower limbs with systematic bedside DUS. More importantly, this
65 rate is as important in our study as in patients with severe COVID-19 and admitted to intensive unit
66 care [3, 4]. This non-invasive procedure may be more accurate to detect DVT than D-dimer levels,
67 which is correlated to COVID-19 severity [7], because they are also increased in the acute phase of
68 stroke with no COVID-19 [8]. Our findings show rates that are more than three times those reported
69 in the stroke literature [8] and suggest that non-severe COVID-19 may increase risk for DVT.

70 Among the factors increasing the risk of DVT in stroke patients it was shown that taken together a
71 higher age, a higher NIHSS before and after treatment, and a longer hospitalization are deleterious
72 [9, 10]. In one hand our findings confirm these results but in the other hand they show a discrepancy
73 since in acute stroke these authors found only 11.5% DVT patients [9]. Literature in severe COVID-19
74 reports a systemic inflammation induced by a cytokine storm favouring a state of hypercoagulability
75 [11, 12], which in turn may be a risk factor of DVT, but it seems overestimated [13]. It was also
76 reported however that the viral infection in COVID-19 affects the venous endothelial cells [14] and
77 induces an endotheliitis [15], which in turn leads to endothelial dysfunction predisposing to pro-
78 coagulant state [16]. Therefore, we hypothesized that in non-severe COVID-19 patients with a
79 neurovascular disease treated with thromboprophylaxis, the peripheral venous thrombotic
80 complications may appear more frequently than in non-COVID patients. Further studies are needed
81 to confirm this hypothesis by comparing data from COVID-19 patients with those of non-COVID-19
82 patients.

83 **Conclusion**

84 We showed for the first time an important prevalence of 38.5% DVT using systematic bedside DUS in
85 neurovascular disease patients with non-severe COVID-19 despite recommended
86 thromboprophylaxis and justified by the absence of reliable biological parameters. We hypothesize
87 that COVID-19 increase the risk of DVT in stroke patients. Since it was suggested that DUS should be
88 performed in all patients and integrated into medical care [3, 4] of COVID-19 patients and
89 considering the risk of DVT in stroke patients and COVID-19 as an additional risk factor for
90 thrombosis [12] we strongly suggest a routine DUS of lower limbs in such situation.

91

92 **Acknowledgement**

93 The authors would thank R Galani PhD for his writing assistance.

94 **Conflict of Interest Statement**

95 All authors declare that they have no conflicts of interest relevant to this manuscript.

96 **Funding Sources**

97 There are no funding source to declare.

98 **Author Contributions**

99 OR designed the study and wrote the manuscript. PPIN, BAT, JD, and BD obtained data. BG and WV
100 critically reviewed the manuscript.

References

- 1 Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels. *Radiology*. DOI: 10.1148/radiol.2020201561.
- 2 Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. DOI: 10.1111/jth.14888.
- 3 Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macias M, Toledo-Samaniego N et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. *Thromb Res*. 2020 192:23-26.
- 4 Ren B, Yan F, Deng Z, Zhang S, Xiao L, Wu M, et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. *Circulation*. 2020 142(2):181-183.
- 5 Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain*. DOI:10.1093/brain/awaa240.
- 6 Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: A longitudinal study. *Radiology*. DOI: 10.1148/radiol.2020200843.
- 7 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis. *Thromb Haemost*. 2020 120(5):876-878.
- 8 Ohara T, Farhoudi M, Bang OY, Koga M, Demchuk AM. The emerging value of serum D-dimer measurement in the work-up and management of ischemic stroke. *Int J Stroke*. 2020 15(2):122-131.
- 9 Wang Y, Shi Y, Dong Y, Dong Q, Ye T, Fang K. Clinical risk factors of asymptomatic deep venous thrombosis in patients with acute stroke. *Clin Appl Thromb Hemost*. 2019 25:1076029619868534.
- 10 Balogun IO, Roberts LN, Patel R, Pathansali R, Kalra L, Arya R. Clinical and laboratory predictors of deep vein thrombosis after acute stroke. *Thromb Res*. 2016 142:33-39.
- 11 Zhang L, Feng X, Zhang D et al. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome. *Circulation*. 2020 142(2),114-128.
- 12 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020 Mar 28;395(10229):1054-1062. Erratum in: *Lancet*. 2020 Mar 28;395(10229):1038.
- 13 Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med*. 2020 46(6):1105-1108.
- 14 Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A et al. Autopsy findings and venous thromboembolism in patients with COVID-19. *Ann Intern Med*. DOI: 10.7326/M20-2003.
- 15 Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020 May 2;395(10234):1417-1418.
- 16 Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N et al. Angiotensin-converting enzyme 2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. *Angiogenesis*. DOI: 10.1007/s10456-020-09730-0.

Table Legend:

Characteristics of neurovascular diseases patients with and without DVT and COVID-19.

	All(n=13)	DVT(n=5)	non-DVT(n=8)
Females, n(%)	8(61.5)	2(40)	6(75)
Age, median(IQR)	67(19-85)	77(71-85)	69.5(19-83)
Antithrombotic therapy before admission, n(%)			
None	9(69.2)	4(80)	5(62.5)
Curative fractioned heparin	1(7.7)		1(12.5)
Aspirin + warfarin	1(7.7)		1(12.5)
Aspirin	1(7.7)	1(20)	
Clopidogrel	1(7.7)		1(12.5)
Biological findings, mean(SD)			
C-reactive protein (mg/l)	38(±11)	45(±20)	34(±14)
White blood cell count (10 ⁹ /l)	9.6(±1.2)	9.9 (±1.5)	9.4(±1.9)
Neutrophil count (10 ⁹ /l)	7.1(±1.1)	7.9(±1.3)	6.6(±1.7)
Lymphocyte count (10 ⁹ /l)	1.6(±0.2)	0.9(±0.2)	2.1(±0.3)
Fibrinogen (g/l)	4.8(±0.6)	4.9(±0.9)	4.7(±0.6)
Neurovascular diseases, n			
Ischemic stroke	10	5	5
Transient ischemic attack	1		1
Cerebral venous thrombosis	1		1
Haemorrhagic Stroke	1		1
Admission median NIHSS, (IQR)	6(0-20)	14(5-20)	3(0-15)
Treatment at admission, n			
Cerebral reperfusion therapies	7		
Intravenous thrombolysis alone	1		1
Intra-arterial thrombolysis alone	1		1
Mechanical thrombectomy			
-with intravenous thrombolysis	3	2	1
-alone	2	1	1
Others			
Reversal anticoagulation	1		1
Intravenous aspirin bolus alone	4	2	2
Effective anticoagulation	1		1
Anticoagulant treatment*, n			
None	1		1
Thromboprophylaxis	9	5	4
Effective anticoagulation	3		3
Discharge			
Death, n	2	2	
Median NIHSS, (IQR)	1(0-11)	3(2-11)	0(0-2)
Median days' hospitalization, (IQR)	9(3-33)	27(9-33)	8(3-17)

n indicates number; IQR, interquartile range; SD, standard deviation. *at admission if reperfusion therapies, at 24 hours if not.
